Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
ISTH DIC subcommittee communication on anticoagulation in COVID-19

Jecko Thachil | Nicole P. Juffermans | Marco Ranucci | Jean M. Connors | Theodore E. Warkentin | Thomas L. Ortel | Marcel Levi | Toshiaki Iba | Jerrold H. Levy

1Department of Haematology, Manchester University Hospitals, Manchester, UK
2Laboratory of Experimental Intensive Care and Anesthesiology, Amsterdam University Medical Center, Amsterdam, The Netherlands
3Department of Intensive Care, OLVG Hospital, Amsterdam, The Netherlands
4Department of Cardiovascular Anesthesia and ICU, IRCCS Policlinico San Donato, San Donato Milanese (Milan, Italy
5Hematology Division, Dana-Farber Cancer Institute, Brigham and Women’s Hospital, Boston, MA, USA
6Department of Pathology and Molecular Medicine, McMaster University, Hamilton, ON, Canada
7Department of Medicine, McMaster University, Hamilton, ON, Canada
8Department of Hematology, Departments of Medicine and Pathology, Duke University Medical Center, Durham, NC, USA
9Department of Medicine and Cardiometabolic Programme-NIHR UCLH/UCL BRC, University College London Hospitals NHS Foundation Trust London, London, UK
10Department of Emergency and Disaster Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan
11Departments of Anesthesiology, Critical Care and Surgery, Duke University School of Medicine, Durham, NC, USA

Correspondence
Toshiaki Iba, Department of Emergency and Disaster Medicine, Juntendo University Graduate School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo (postal code: 113-8421), Japan.
Email: toshiiba@juntendo.ac.jp

Abstract
Hypercoagulability is an increasingly recognized complication of SARS-CoV-2 infection. As such, anticoagulation has become part and parcel of comprehensive COVID-19 management. However, several uncertainties exist in this area, including the appropriate type and dose of heparin. In addition, special patient populations, including those with high body mass index and renal impairment, require special consideration. Although the current evidence is still insufficient, we provide a pragmatic approach to anticoagulation in COVID-19, but stress the need for further trials in this area.

KEYWORDS
anticoagulant, coagulopathy, Covid-19, D-dimer, prothrombin time

1 | INTRODUCTION

Morbidity and mortality secondary to COVID-19 is increasing worldwide. Venous thromboembolism (including pulmonary embolism), arterial thrombosis, and microvascular thrombi appear to contribute to adverse outcomes. One of the key interventions that appears to be effective in reducing mortality associated with thrombosis in non-COVID-19 settings is anticoagulant therapy. Accordingly, the International Society on Thrombosis and Haemostasis published an interim guideline that recommended the use of prophylactic anticoagulation with low molecular weight heparin (LMWH) in all patients admitted with COVID-19 in the absence of contraindications.
With the increasing experience of health care providers in managing COVID-19 patients, several questions have arisen about the use of anticoagulation that we address in this practice communication. Although possible solutions are suggested, we stress the need for well-designed randomized studies (performed rapidly) to produce evidence-based recommendations. The following recommendations are for adult patients only.

2 | UNFRACTIONATED HEPARIN OR LOW MOLECULAR WEIGHT HEPARIN?

In the study by Tang et al, a minority of all COVID-19 patients received LMWH in prophylactic doses, with relatively few given unfractionated heparin (UFH). The use of LMWH reflects the evolving practice worldwide toward LMWH becoming the standard of care for the prevention and treatment of thromboembolism versus UFH because of better bioavailability, fixed dosing, decreased risk of heparin-induced thrombocytopenia (HIT), and osteoporosis. However, LMWH can accumulate with renal impairment and has a longer half-life than UFH. Hence, in patients with severe renal impairment, at a high-risk of bleeding, or the need to undergo invasive procedures, UFH is preferred, which may be particularly relevant in critically ill COVID-19 patients, in whom coagulopathy is the most severe.

When using UFH, however, numerous variables ranging from preanalytic issues (sample collection and processing), and re-agent differences can influence activated partial thromboplastin time (aPTT) measurements. The aPTT may be prolonged in some COVID-19 patients because of consumptive coagulopathy in the most critically ill and possibly from the presence of a lupus anticoagulant. A recent report implicating antiphospholipid antibodies in COVID-19 patients with thrombotic events found elevated aPTT levels and presence of anticardiolipin and anti-β2-glycoprotein antibodies, although lupus anticoagulant tests were negative. Another paper noted 20% of patients had a prolonged aPTT, most of which were due to lupus anticoagulants. A French group observed 45% positivity in lupus anticoagulant tests in 56 patients diagnosed with COVID-19. Whether these antibodies are pathogenic and result in thrombosis (including arterial thrombosis) remains to be determined.

One potential concern with the use of UFH in COVID-19 patients is the possible development of heparin resistance in the setting of an acute phase response. In COVID-19 and other inflammatory states, acute phase reactants, including fibrinogen and C-reactive protein, are elevated. It has been shown that increased fibrinogen levels and other heparin-binding acute-phase reactants create a prohemostatic environment that can antagonize the anticoagulant effects of heparin, with hyperfibrinogenemia a key factor causing heparin resistance. Heparin resistance is defined as the requirement of high doses of UFH (daily dose in excess of 35 000 units/d) to achieve a therapeutic range. This phenomenon occurs because of heparin’s ability to bind to various acute-phase plasma proteins (increased in COVID-19), as well as macrophages and endothelial cells, which are both activated in COVID-19. Although low antithrombin levels are another potential reason for heparin resistance, moderate to severe decreased antithrombin levels are unusual in COVID-19 patients, with most patients having plasma levels within the low-normal range of ~80%. However, Ranucci et al did report antithrombin levels <60% in two of 16 patients in their analysis of COVID-19 critically ill subjects. In addition, thrombocytosis, which has been noted in COVID-19, possibly from excessive thrombopoietin production of the liver, has also been suggested as a reason for heparin resistance. A practical solution for “overcoming” heparin resistance is to measure both aPTT and a concomitant anti-factor Xa heparin level. If monitoring is impractical, alternate agents such as longer-acting, non-aPTT adjusted subcutaneous fondaparinux or danaparoid may be alternatives if the renal function is normal. Prophylactic-dose LMWH (dalteparin) has been studied in critically ill patients even with markedly impaired renal function without monitoring and no adverse effects.

3 | STANDARD PROPHYLACTIC-DOSE ANTICOAGULATION?

Clinical experience in COVID-19 suggests there are anticoagulation failures in patients already receiving prophylactic anticoagulation. In a recently published study, despite systematic thromboprophylaxis, 31% of the 184 patients in critical care units with COVID-19 developed thrombotic complications. In an update of this cohort, the cumulative incidence of arterial and venous thromboembolism was 49% (95% confidence interval, 41-57). Other studies have found similarly marked increase in the incidence of venous thromboembolism (VTE) in patients requiring intensive care unit (ICU) care that exceed similarly cared for ICU patients without COVID-19, including comparison to past influenza patients. This could be due to several reasons including (a) COVID-19-specific coagulation changes with extensive coagulation activation for which prophylactic dosing may be insufficient, (b) thromboembolism had already developed before starting anticoagulation, or (c) inadequate dosing (high body mass index or inaccurate dosing). In the setting of critically ill patients requiring mechanical ventilation, immobilization can occur from deep sedation and muscle paralysis. Also, the use of high-pressure ventilation settings resulting in high intrathoracic pressure may impair pulmonary perfusion. Significant controversy has developed regarding an empiric increase in the dose of heparin, especially in the following situations (Figure 1):

1. Worsening of the clinical picture manifest as increasing oxygen requirements, which may be due to pulmonary microthrombi
2. Suspicion of pulmonary thromboembolism based on abrupt development of hypoxemia, new tachycardia, and right heart strain seen on echocardiogram. Heightened suspicion should be maintained in ALL patients;
3. Need for ICU care and ventilatory support as the cumulative incidence of VTE in ICU patients has been found to be higher than those not requiring ICU care.\textsuperscript{22,24}

If imaging can be performed, and there is definite evidence of thrombi, therapeutic anticoagulation should be administered. In those patients for whom pulmonary thromboembolism is highly likely based on clinical findings but imaging is not feasible, an increase to therapeutic-dose anticoagulation may be appropriate. Therapeutic-dose anticoagulation in a large cohort of hospitalized patients with COVID-19 was associated with a reduced risk of mortality (adjusted hazard ratio of 0.86 per day; 95% confidence interval, 0.82-0.89; \( P < .001 \)).\textsuperscript{25} In addition, the higher dose reduced the incidence of mechanically ventilated patients (in-hospital mortality of 29.1% compared with 62.7% in those who did not receive anticoagulation).\textsuperscript{25} However, this retrospective review of hospital system data has many limitations, including lack of information on patient selection for therapeutic-dose anticoagulation, indication for anticoagulation, severity of illness, and other unknown confounding variables. Other centers are using “intermediate-dose” anticoagulation in patients who have no evidence of VTE but require ICU care based on the increased incidence of VTE despite standard-dose thromboprophylaxis.\textsuperscript{22,23} Although Goyal et al have shown that critically ill patients with COVID-19 may not have higher incidence of thrombosis compared with other critically ill patients,\textsuperscript{26} the reports from several different countries are showing a remarkably increased thrombotic risk in these patients and “failure” of standard dose prophylactic anticoagulation.

\textbf{FIGURE 1} Suggested algorithm for anticoagulation in patients with COVID-19

\textbf{TABLE 1} Bleeding adverse events under anticoagulation in COVID-19 patients

| Source                | Cases or Incidence of Bleeding                                                                 | Anticoagulation                              |
|-----------------------|---------------------------------------------------------------------------------------------|----------------------------------------------|
| Bargellini et al\textsuperscript{47} | Four consecutive patients with spontaneous bleedings underwent endovascular embolization. | 6000 IU LMWH/12 h or 8000 IU/12 h            |
| Carroll et al\textsuperscript{48}   | Two cases of patients developed catastrophic intracranial hemorrhage and cerebral edema.  | Anti-Xa levels: <0.73 and 0.62 IU/mL          |
| Al-Samkari et al\textsuperscript{49} | Overall and major bleeding rates were 4.8% (19/400 cases) and 2.3% (3/144 cases).          | Standard-dose prophylactic anticoagulation   |
Hence, until trials prove otherwise, the authors suggest an intensification of the prophylactic dose of heparin if patients require critical care support if there are no contraindications. The risk of bleeding under anticoagulation in COVID-19 patients is summarized in Table 1.

If therapeutic anticoagulation with UFH is chosen, the issue of “aPTT confounding” should be considered; this is a situation where an underlying condition (e.g., liver impairment, lupus anticoagulant) may cause pretreatment aPTT elevations and patients may have “therapeutic” aPTT values, but where the anticoagulant level is actually subtherapeutic.19

4 | EXTRACORPOREAL FILTER CLOTS OR OCCLUSION

Health care providers are noticing in COVID-19 patients an increase in filter occlusion and thrombosis with extracorporeal circuits including hemofiltration or extracorporeal membrane oxygenation, despite routine anticoagulation.27 Contact activation and the complement system are both involved in thrombin generation in patients who require dialysis or extracorporeal membrane oxygen (ECMO).28,29 Because the inflammatory process is closely linked to both these pathways, intense inflammation in COVID-19 could predispose to filter clots or occlusion.29,30 Possible management approaches include administration of higher doses of heparin as well as more accurately assessing the anticoagulant effects of heparin. Additional therapies that may also be considered include complement inhibitors and possibly agents that can inhibit the contact pathway of the coagulation cascade. For patients on ECMO or with continuous veno-venous hemofiltration, therapeutic anticoagulation may be appropriate if there is evidence of clots in the extracorporeal circuits.

5 | PATIENTS WITH RENAL IMPAIRMENT

Abnormalities in renal function are rare at least in the early phases of the COVID-19 infection.11 But there may be patients who already have known kidney problems or can develop renal impairment secondary to the critical illness or the use of hydroxychloroquine. If the patient is receiving LMWH in treatment doses, the amount should be adjusted based on anti-Xa measurements to avoid drug accumulation.31 Some experts recommend switching to UFH in this clinical situation, which may be reasonable, but as discussed before, ensuring rapid and adequate anticoagulation is imperative.7 Alternatives to UFH include renally adjusted dose danaparoid, argatroban, or bivalirudin.32

6 | SPECIAL PATIENT POPULATION: OBESITY

Obesity with body mass index > 35 in patients with COVID-19 appears to be a poor prognostic indicator.33 A possible explanation is the higher susceptibility to inflammation and thrombotic complications in obese patients. Debate exists about the appropriate dose for prophylaxis in obese patients with limited data to guide care. These patients should be given a weight-adjusted appropriate prophylactic dose at admission, with an increase to intermediate intensity or full therapeutic dose based on clinical parameters (Figure 1).34,35 Treatment doses also require adjustment for weight.36,37

7 | THE ROLE OF POINT-OF-CARE TESTING

Point-of-care testing, including viscoelastic testing, has been used in the critical care setting to guide transfusion of blood products in patients undergoing cardiothoracic surgery, liver transplantation surgery, massive transfusion protocols for trauma, and postpartum haemorrhage.28 Point-of-care testing has never been validated for use in patients to predict risk of bleeding or thrombosis, although several studies have examined this aspect.39 Ranucci et al reported hemostatic changes in patients with COVID-19 pneumonia using Quantra Hemostasis analyser (Quantra System, HemoSonics LLC), using a device based on lower manipulation of the samples because blood is directly suctioned from citrated vials.17 The study reported increased clot firmness consistent with hypercoagulability, but decreased biomarkers with a higher level of anticoagulation; and clopidogrel if platelet count >400 000 cells/μL. This small study provides important initial information, but requires validation using larger patient numbers. Thromboelastography parameters in an Italian study of 24 patients were also suggestive of hypercoagulability, as shown by decreased R time and K value, and increased K angle and MA.40 ROTEM analysis by Pavoni and colleagues also demonstrated a state of severe hypercoagulability not obvious on standard coagulation parameters.41

8 | HEPARIN-INDUCED THROMBOCYTOPENIA

The use of heparin can be associated with HIT, a well-known side effect of this drug.42 HIT is also more common in patients who have associated inflammatory conditions, a finding that may reflect increased platelet activation in patients receiving UFH or therapeutic doses of LMWH.43 Because thrombocytopenia is uncommon in patients with COVID-19, a significant drop in platelet count that begins 5 or more days after starting UFH or LMWH should raise suspicion for HIT, especially if additional explanations such as bacterial superinfection or consumption coagulopathy has been excluded. Moreover, development of clinically evident venous or arterial thrombosis in a patient receiving heparin should also prompt consideration of HIT.44 Until the diagnosis of HIT can be confirmed, heparin exposure that includes line flushes should be discontinued and substituted with an alternate anticoagulant such as danaparoid,
fondaparinux, bivalirudin, or argatroban.\textsuperscript{42} Recently, high-dose intravenous immunoglobulin has been advocated as an adjunctive treatment for severe HIT,\textsuperscript{45} and used with anecdotal success in deteriorating patients with COVID-19 infection.\textsuperscript{46}

### LIMITATIONS OF THE PUBLISHED STUDIES ON ANTICOAGULATION IN COVID-19

Overall, all of the existing studies about anticoagulation type and dosing in COVID-19 share the same limitations: (a) the retrospective nature and (b) a limited population size. These two factors led to a lack of information on the effects of different anticoagulation regimens in terms of containment of thromboembolic complications. The recommendations from the different societies are summarized in Table 2. Several trials are under way examining the type, and dose of heparin in patients admitted with COVID-19. Additional antithrombotic agents to heparin are also under evaluation.

### SUMMARY

Thrombosis is a major problem in patients with COVID-19 requiring hospitalization. Anticoagulation is important in these patients but questions have arisen about the appropriate type, dose, and timing of anticoagulation. Existing guidelines and consensus documents are providing general suggestions on the LMWH dose based on the severity of the disease and the thrombotic risk, but a link between coagulation markers and anticoagulation regimen is still lacking. Many clinical trials addressing these questions are in progress; participation in these trials is encouraged to determine the best management strategies for COVID-19 patients. Increasing knowledge with rapid sharing is required to adequately care for patients in this pandemic.
ACKNOWLEDGEMENTS
None

CONFLICT OF INTEREST
Dr. Ortel has received royalties from Up To Date; has provided consulting services to Instrumentation Laboratory; and has received research funding from Instrumentation Laboratory, Siemens, Stago, and Ergomed. Dr. Warkentin has received lecture honoraria from Alexion and Instrumentation Laboratory and royalties from Informa (Taylor & Francis); has provided consulting services to Aspen Global, Bayer, CSL Behring, Ergomed, and Octapharma; has received research funding from Instrumentation Laboratory; and has provided expert witness testimony relating to heparin-induced thrombocytopenia (HIT) and non-HIT thrombocytopenic and coagulopathic disorders. Dr. Thachil has received honoraria from Bayer, BMS-Pfizer, Daichii-Sankyo, Boehringer, Mitsubishi, Novo Nordisk, Octapharma, Novartis, Amgen, Norgine, Alexion, Sobi, and CSL-Behring. The remaining authors state that they have no conflicts of interests.

AUTHOR CONTRIBUTIONS
Jeco Thachil conceived the paper and drafted the first manuscript. Nicole P. Juffermans, Marco Ranucci, Jean M. Connors, Theodore E. Warkentin, Thomas L. Ortel, Marcel Levi, Toshiaki Iba, and Jerrold H. Levy made critical comments. All authors approved the final submission.

ORCID
Marco Ranucci https://orcid.org/0000-0002-4915-3572
Jean M. Connors https://orcid.org/0000-0001-6445-582X
Theodore E. Warkentin https://orcid.org/0000-0002-8046-7588
Thomas L. Ortel https://orcid.org/0000-0001-6193-4585
Toshiaki Iba https://orcid.org/0000-0002-0525-4088

REFERENCES
1. Cui S, Chen S, Li X, Liu S, Wang F. Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia. J Thromb Haemost. 2020;18(6):1421-1424.
2. Klok FA, Kruip MJHA, van der Meer NJM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res. 2020;200:49-3848(20):30120-30121.
3. Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulant treat- ment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost. 2020;18(10):1094-1099.
4. Thachil J, Tang N, Gando S, et al. ISTH interim guidance on recogni- tion and management of coagulopathy in COVID-19. J Thromb Haemost. 2020;18(10):1023-1026.
5. Hirsh J, Warkentin TE, Shaughnessy SG, et al. Heparin and low-molecular weight heparin: mechanism of action, pharmacokinetics, dosing, monitoring, efficacy and safety. Chest. 2001;119(1Suppl):645-695.
6. Hirsh J, Bauer KA, Donati MB, Gould M, Samama MM, Witzt JI. Parenteral anticoagulants: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest. 2008;133(6):1415-1595.
7. Smythe MA, Priziola J, Dobesh PP, Wirth D, Cuker A, Wittkowsky AK. Guidance for the practical management of the heparin anti- coagulants in the treatment of venous thromboembolism. J Thromb Thrombolysis. 2016;41(1):165-186.
8. Zhang Y, Xiao M, Zhang S, et al. Coagulopathy and antiphos- pholipid antibodies in patients with Covid-19. New Engl J Med. 2020;1105:208-213.
9. Bowles L, Plutton S, Yarney N, et al. Lupus anticoagulant and ab- normal coagulation tests in patients with Covid-19. N Engl J Med. 2020;383(3):288-290.
10. Harzallah I, Deblquis A, Dréonou B. Lupus anticoagulant is frequent in patients with Covid-19 [published online ahead of print April 23, 2020]. J Thromb Haemost. 2020;18(8):2064-2065.
11. Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020;18(4):844-847.
12. Guan WJ, Ni ZY, Hu Y, et al. China medical treatment expert group for Covid-19. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382(18):1708-1720.
13. Harr JN, Moore EE, Chin TL, et al. Postinjury hyperfibrinogenemia compromises efficacy of heparin-based venous thromboembolism prophylaxis. Shock. 2014;41(1):33-39.
14. Levine MN, Hirsh J, Gent M, et al. A randomized trial comparing activated thromboplastin time with heparin assay in patients with acute venous thromboembolism requiring large daily doses of heparin. Arch Intern Med. 1994;154:49-56.
15. Finley A, Greenberg C. Review article: heparin sensitivity and resis- tance: management during cardiopulmonary bypass. Anesth Analg. 2013;116(6):1210-1222.
16. Chlebowski MM, Baltagi S, Carlson M, Levy JH, Spinella PC. Clinical controversies in anticoagulation monitoring and antithrombin sup- plementation for ECMO. Crit Care. 2020;24(1):19.
17. Ranucci M, Ballotta A, Di Dedda U, et al. The procoagulant pattern of patients with Covid-19 acute respiratory distress syndrome. J Thromb Haemost. 2020;18(7):1747-1751.
18. Koster A, Zittermann A, Schirmer U. Heparin resistance and exces- sive thrombocytosis. Anesth Analg. 2013;117(5):1262.
19. Warkentin TE. Anticoagulant failure in coagulopathic patients: PTT confounding and other pitfalls. Expert Opin Drug Saf. 2014;13(1):25-43.
20. Koster A, Faraoni D, Levy JH, Argatroban and bivalirudin for perioperative anticoagulation in cardiac surgery. Anesthesiology. 2018;128(2):390-400.
21. Cook D, Meade M, Guyatt G, et al. PROTECT investigators for the Canadian critical care trials group and the Australian and New Zealand intensive care society clinical trials group, Dalteparin versus unfractionated heparin in critically ill patients: PTT confounding and other pitfalls. Expert Opin Drug Saf. 2014;13(1):25-43.
22. Koster A, Faraoni D, Levy JH. Argatroban and bivalirudin for perioperative anticoagulation in cardiac surgery. Anesthesiology. 2018;128(2):390-400.
23. Cook D, Meade M, Guyatt G, et al. PROTECT investigators for the Canadian critical care trials group and the Australian and New Zealand intensive care society clinical trials group, Dalteparin versus unfractionated heparin in critically ill patients: PTT confounding and other pitfalls. Expert Opin Drug Saf. 2014;13(1):25-43.
24. Helms J, Tacquard C, Severac F, et al. High risk of thrombosis in patients with severe novel coronavirus pneumonia. J Thromb Haemost. 2020;18(8):1995–2002.
25. Middeldorp S, van Haaps TF, et al. Incidence of venous thromboembolism associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020;18(4):844-847.
26. Goyal P, Choi JJ, Pinheiro LC, et al. Clinical characteristics of Covid-19 in New York City. N Engl J Med. 2020;382(24):2372-2374.
27. Wright FL, Vogler TO, Moore EE, et al. Fibrinolysis shutdown correlates to thromboembolic events in severe COVID-19 infection. J Am Coll Surg. 2020;31072-7515(20):30400-30402.

28. Colman RW, Schmaier AH. Contact system: a vascular biology modulator with anticoagulant, profibrinolytic, antiadhesive, and proinflammatory attributes. Blood. 1997;90(10):3819-3843.

29. Ruan CC, Gao PJ. Role of complement-related inflammation and vascular dysfunction in hypertension. Hypertension. 2019;73(5):965-971.

30. Maas C, Renne T. Coagulation factor XII in thrombosis and inflammation. Blood. 2018;131(17):1903-1909.

31. Favaloro EJ, Bonar R, Aboud M, et al. How useful is the monitoring of (low molecular weight) heparin therapy by anti-Xa assay? A laboratory perspective. Lab Hematol. 2005;11(3):157-162.

32. Garcia DA, Baglin TP, Weitz JI, Samama MM. Parenteral anticoagulants: antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence based clinical practice guidelines. Chest. 2012;141(2):e245-e435).

33. Tamara A, Tahapary DL. Obesity as a predictor for a poor prognosis of COVID-19: a systematic review. Diabetes Metab Syndr. 2020;14(4):655-659.

34. Lee YR, Blanco DD. Efficacy of standard dose unfractionated heparin for venous thromboembolism prophylaxis in morbidly obese and non-morbidly obese critically ill patients. J Thromb Thrombolysis. 2017;44(2):386-391.

35. Shlensky JA, Thurber KM, O’Meara JG, et al. Unfractionated heparin infusion for treatment of venous thromboembolism based on actual body weight without dose capping. Vasc Med. 2020;25(1):47-54.

36. Ebied AM, Li T, Axelrod SF, Tam DJ, Chen Y. Intravenous unfractionated heparin dosing in obese patients using anti-Xa levels. J Thromb Thrombolysis. 2020;49(2):206-213.

37. Sebaaly J, Covert K. Enoxaparin dosing at extremes of weight: literature review and dosing recommendations. Ann Pharmacother. 2018;52(9):898-909.

38. Curry NS, Davenport R, Pavord S, et al. The use of viscoelastic haemostatic assays in the management of major bleeding: a British Society for Haematology guideline. Br J Haematol. 2018;182(6):789-806.

39. Levi M, Hunt BJ. A critical appraisal of point-of-care coagulation testing in critically ill patients. J Thromb Haemost. 2015;13(11):1960-1967.

40. Panigada M, Bottino N, Tagliabue P, et al. Hypercoagulability of COVID-19 patients in intensive care unit. a report of thromboelastography findings and other parameters of hemostasis. J Thromb Haemost. 2020;18(7):1738-1742.

41. Pavoni V, Giansello L, Pazzi M, Stera C, Meconi T, Frigieri FC. Evaluation of coagulation function by rotation thromboelastometry in critically ill patients with severe COVID-19 pneumonia. J Thromb Thrombolysis. 2020;50(2):281-286.

42. Cuker A, Arepally GM, Chong BH, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia. Blood Adv. 2018;2(22):3360-3392.

43. Arepally GM. Heparin-induced thrombocytopenia. Blood. 2017;129(21):2864-2872.

44. Warkentin TE. Think of HIT when thrombosis follows heparin. Chest. 2006;130(3):631-632.

45. Warkentin TE. High-dose intravenous immunoglobulin for the treatment and prevention of heparin-induced thrombocytopenia: a review. Exp Rev Hematol. 2019;12(8):685-698.

46. Cao W, Liu X, Bai T, et al. High-dose intravenous immunoglobulin as a therapeutic option for deteriorating patients with coronavirus disease 2019. Open Forum Infect Dis. 2020;7(3):ofaa102.

47. Bargellini I, Cervelli R, Lunardi A, et al. Spontaneous bleedings in COVID-19 patients: an emerging complication. Cardiovasc Interv Radiol. 2020;43(7):1095-1096.

48. Carroll E, Lewis A. Catastrophic intracranial hemorrhage in two critically ill patients with COVID-19 [published online ahead of print May 26, 2020]. Neurocrit Care. 1-5.

49. Al-Samkari H, Karp Leaf RS, Dzik WH, et al. COVID and coagulation: bleeding and thrombotic manifestations of SARS-CoV2 infection. Blood. 2020;136(4):489-500.

50. Jin YH, Cai L, Cheng ZS, et al. A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version). Mil Med Res. 2020;7(1):4.

51. Song JC, Wang G, Zhang W, et al. Chinese expert consensus on diagnosis and treatment of coagulation dysfunction in COVID-19. Mil Med Res. 2020;7(1):19.

52. Vivas D, Roldán V, Esteve-Pastor MA, et al. Recommendations on antithrombotic treatment during the COVID-19 pandemic. Position statement of the Working Group on Cardiovascular Thrombosis of the Spanish Society of Cardiology [published online ahead of print April 22, 2020]. Rev Esp Cardiol. 2020;73(9):749-757.

53. Bikdeli B, Madhavan MV, Jimenez D, et al. COVID-19 and thrombotic or thromboembolic disease: implications for prevention, anti-thrombotic therapy, and follow-up: JACC state-of-the-art review. J Am Coll Cardiol. 2020;75(23):2950-2973.

54. Spyropoulos AC, Levy JH, Ageno W, et al. Scientific and standardization committee communication: clinical guidance on the diagnosis, prevention and treatment of venous thromboembolism in hospitalized patients with COVID-19 [published online ahead of print May 27, 2020]. J Thromb Haemost. 2020;18(8):1859-1865.

55. Moores LK, Tritschler T, Brosnahan S, et al. Prevention, diagnosis, and treatment of VTE in patients With COVID-19. Chest. 2020;S0002-3692(20):31625-31631.

How to cite this article: Thachil J, Juffermans NP, Ranucci M, et al. ISTH DIC subcommittee communication on anticoagulation in COVID-19. J Thromb Haemost. 2020;18:2138-2144. https://doi.org/10.1111/jth.15004